Core Viewpoint - The announcement of the clinical development of ASC36, a novel oral glucagon-like peptide-1 (GLP-1) receptor agonist, marks a significant advancement for the company in the metabolic disease sector, showcasing its proprietary oral peptide delivery enhancement technology [1] Company Summary - The company's stock, Gilead Sciences-B (01672), saw an increase of nearly 8%, with a current price of HKD 17.72 and a trading volume of HKD 36.79 million [1] - The board of directors has selected ASC36 for clinical development, with plans to submit an Investigational New Drug (IND) application to the FDA in the second quarter of 2026 for obesity treatment [1] - ASC36 is developed using the company's AI-assisted drug discovery technology (AISBDD), representing a key transition from platform capability to candidate drug [1]

Group 1 - The Hang Seng Index rose by 0.43%, gaining 116 points to close at 27,299 points, while the Hang Seng Tech Index increased by 1.10% [1] - Xiaomi Group-W (01810) saw a rise of over 4%, with the new generation SU7 expected to launch in April [1] - The first-day listing of Xian Dao Intelligent (00470) increased by 0.44%, while fishing company Lexin Outdoor (02720) surged by 33% on its second day of trading [1] - The Kintor Group (00148) and Kintor Laminates (01888) experienced gains of 5% and 14% respectively, driven by expected high growth in copper-clad laminate performance by 2025 [1] - The precious metals sector saw gains, with Wan Guo Gold Group (03939) rising over 9% to reach a new high, benefiting from increased gold prices [1] - Tungsten prices continued to rise, with tungsten oxide increasing by 20,000 yuan per ton and ammonium paratungstate rising by 10,000 yuan per ton, leading to a surge of over 12% for Jiaxin International Resources (03858) [1] - China Duty Free Group (01880) rose over 5% following a strong start to the Spring Festival travel season for duty-free shopping in Hainan [1] Group 2 - Gilead Sciences-B (01672) increased by over 6%, with plans to submit an IND for ASC36 oral tablets for obesity treatment to the FDA in the second quarter [2] - Jinli Permanent Magnet (06680) rose over 7% as rare earth prices continue to climb, with institutions predicting a dual increase in valuation and performance for the sector [3] - Mongol Mining (00975) surged over 11% as its BKH gold mine ramped up production and dividend restrictions were gradually lifted [4] - Semiconductor Manufacturing International Corporation (00981) fell by 3.63% post-earnings, with Goldman Sachs indicating that its first-quarter gross margin guidance was below expectations [5] - Health 160 (02656) plummeted by 33%, retracting most of its gains for the year, with its total market value briefly falling below 20 billion HKD [6]

Core Viewpoint - The stock of Gilead Sciences-B (01672) has increased over 30% in the month, with a current price of HKD 18.24 and a trading volume of HKD 17.99 million, following the announcement of its first oral glucagon-like peptide-1 receptor agonist, ASC36, entering clinical development [1] Group 1 - The company announced on February 11 that it has selected ASC36 oral tablets for clinical development, with plans to submit an Investigational New Drug (IND) application to the FDA in the second quarter of 2026 for obesity treatment [1] - ASC36 is expected to have superior oral bioavailability and efficacy compared to a recently FDA-approved GLP-1R agonist, potentially allowing for lower dosing [1] - The weight loss effect per milligram of ASC36 peptide is anticipated to be more effective, which may lead to lower manufacturing costs due to scalability advantages [1] Group 2 - ASC36 is developed using the company's proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) technology [1] - The oral tablet formulation of ASC36 has been optimized using the company's proprietary POTENT technology for effective oral peptide delivery [1]

Core Viewpoint - The stock of Gilead Sciences-B (01672) has increased by over 30% in the month, with a current rise of 6.42% to HKD 18.24, driven by the announcement of its first oral glucagon-like peptide-1 receptor agonist, ASC36, entering clinical development [1] Company Developments - On February 11, Gilead Sciences-B announced that its board has selected ASC36 oral tablets for clinical development [1] - The company plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ASC36 in the second quarter of 2026 for the treatment of obesity [1] Product Advantages - ASC36 is expected to have superior oral bioavailability and efficacy compared to a recently FDA-approved GLP-1R agonist, potentially allowing for lower dosing [1] - Each milligram of ASC36 peptide is anticipated to provide better weight loss effects, which may lead to lower manufacturing costs due to scalability advantages [1] Technology and Innovation - ASC36 is developed using Gilead's proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) technology [1] - The oral tablet formulation of ASC36 has been optimized using Gilead's proprietary POTENT technology for effective oral peptide delivery [1]

Group 1 - The core point of the article is that Gilead Sciences-B (01672) has deposited shares worth HKD 1.129 billion into Standard Chartered Bank (Hong Kong), representing 6.93% of its total shares [1] - Gilead Sciences-B announced that its board has selected its first oral amylin receptor agonist peptide, ASC36 oral tablets, for clinical development [1] - The company expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ASC36 oral tablets for the treatment of obesity in the second quarter of 2026 [1]

Core Viewpoint - The company, Gilead Sciences-B (01672.HK), has selected its first oral glucagon-like peptide-1 receptor agonist, ASC36 oral tablets, for clinical development, with plans to submit an Investigational New Drug (IND) application to the FDA in Q2 2026 for obesity treatment [1][2] Group 1 - ASC36 oral tablets have shown an absolute oral bioavailability of 6% to 8% in non-human primate studies, utilizing Gilead's proprietary oral peptide delivery enhancement technology (POTENT) [1] - In non-human primates, ASC36 oral tablets led to an average weight reduction of up to 13.2% relative to baseline after 7 days of once-daily dosing, significantly reducing food intake [1] - In a head-to-head study using a diet-induced obesity (DIO) rat model, ASC36 demonstrated weight loss effects that were approximately 32% and 91% greater compared to eloralintide and petrelintide, respectively [1] Group 2 - The company has three key glucagon-like peptide-1 candidates: oral small molecule GLP-1, oral GLP-1 peptide, and monthly subcutaneous GLP-1 peptide, with ASC36 oral tablets being a significant GLP-1 agonist [2] - Gilead's competitive and differentiated product pipeline is supported by three proprietary technology platforms: AISBDD, Ultra-Long-Acting Platform (ULAP), and POTENT, aimed at addressing diverse treatment needs for obesity and other metabolic diseases [2]

Core Viewpoint - The company, Gilead Sciences, has announced the selection of its first oral glucagon-like peptide-1 (GLP-1) receptor agonist, ASC36, for clinical development, with plans to submit an Investigational New Drug (IND) application to the FDA by Q2 2026 [1] Group 1: Drug Development and Clinical Trials - ASC36 oral tablets are developed using Gilead's proprietary oral peptide delivery enhancement technology (POTENT) [1] - The absolute oral bioavailability of ASC36 in non-human primates is 8% for the 10 mg dose and 6% for the 25 mg dose, with elimination half-lives of 116 hours and 167 hours respectively, supporting less frequent dosing [1][2] - The drug has shown significant weight loss effects in both non-human primates and diet-induced obesity (DIO) rat models, achieving up to a 13.2% reduction in average body weight relative to baseline after 7 days of treatment [2] Group 2: Comparative Efficacy and Manufacturing Advantages - ASC36 demonstrated approximately 32% and 91% greater weight loss compared to eloralintide and petrelintide, respectively, in head-to-head DIO rat models [2] - The potential for superior oral bioavailability and efficacy may allow for lower dosing compared to recently FDA-approved GLP-1R agonists, which could lead to cost advantages in large-scale production [2] - ASC36 is part of a broader pipeline of insulin candidates, including oral small molecule insulin and monthly subcutaneous insulin peptides, leveraging Gilead's three proprietary technology platforms: AI-assisted structure-based drug discovery (AISBDD), ultra-long-acting drug development platform (ULAP), and POTENT [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Ascletis Pharma Inc. 歌禮製藥有限公司 ASC36口服片由歌禮利用其專有的口服多肽遞送增強技術(POTENT)開發而成。 在非人靈長類動物中，10毫克ASC36口服片在每只動物中每日一次給藥，給藥7 天後，穩態下的絕對口服生物利用度(absolute oral bioavailability)[1]為8%，消除半 衰期(elimination half-life)達116小時；25毫克ASC36口服片在每只動物中每日一 1 － 在非人靈長類動物研究中，通過利用歌禮口服多肽遞送增強技術(POTENT)， ASC36口服片在穩態下的絕對口服生物利用度達6%至8%。 － 在非人靈長類動物中，ASC36口服片每日一次給藥7天後，使相對基線的平 均體重下降高達13.2%。ASC36片亦顯著減少了食物攝入。 － 在一項頭對頭飲食誘導肥胖(DIO)大鼠模型中，與eloralintide和petre ...